Pharmaceutical drug
![]() | |
Clinical data | |
---|---|
Other names | SC-14266 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous |
ATC code | |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.868 ![]() |
Chemical and physical data | |
Formula | C22H29KO4 |
Molar mass | 396.568 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]
Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]
In the UK, it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.
See also
[edit]References
[edit]- ^ Selye H (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
- ^ Hill RA, Makin HL, Kirk DN, Murphy GM (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
- ^ Burger A, Wolff ME (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
- ^ a b Waldmann C, Soni N, Rhodes A (27 November 2008). "Diurectics and the Critical Ill". Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
- ^ Santambrogio R, Barabino M, Opocher E (21 June 2017). "Non-resection: Radiofrequency Ablation, Cryo, Microwave". In Bonjer HJ (ed.). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
- ^ Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
Sulfonamides (and etacrynic acid) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Potassium-sparing (at CD) |
| ||||||||
Osmotic diuretics (PT, DL) | |||||||||
Vasopressin receptor inhibitors (DCT and CD) | |||||||||
Other | |||||||||
Combination products | |||||||||
|
Mineralocorticoids | |
---|---|
Antimineralocorticoids | |
Synthesis modifiers | |
|
MRTooltip Mineralocorticoid receptor |
| ||||
---|---|---|---|---|---|
PRTooltip Progesterone receptor |
| ||||||
---|---|---|---|---|---|---|---|
mPRTooltip Membrane progesterone receptor (PAQRTooltip Progestin and adipoQ receptor) |
| ||||||
ARTooltip Androgen receptor |
| ||||||
---|---|---|---|---|---|---|---|
GPRC6A |
| ||||||